This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LAVA LAVA Therapeutics (LAVA) Stock Price, News & Analysis Add Share Share Stock Analysis Stock AnalysisBuy This Stock About LAVA Therapeutics Stock (NASDAQ:LAVA) 30 days 90 days 365 days Advanced Chart Get LAVA Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMagma Design Automation, Inc. (Magma) provides electronic design automation (EDA) software products and related services. Its software enables chip designers to reduce the time it takes to design and produce integrated circuits used in the communications, computing, consumer electronics, networking and semiconductor industries. Its flagship products consist of a digital integrated solution for the chip development cycle, from initial design through physical implementation. Magma's flagship Talus family of products, its Tekton static timing analyzer and QCP extractor and, its Quartz family of sign-off and verification tools combine into one integrated chip design and verification flow, from what has been separate logic design, physical design, and analysis and sign-off processes. Its Titan platform for custom integrated chip design provides an integrated chip-finishing solution for mixed-signal designs. In February 2012, Synopsys, Inc. acquired the Company.Read More… Receive LAVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LAVA Stock News HeadlinesLava Therapeutics expects $1M of expenses related to restructuring planMarch 28, 2025 | markets.businessinsider.comJMP Securities Sticks to Its Hold Rating for LAVA Therapeutics (LVTX)March 28, 2025 | markets.businessinsider.comNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.June 29 at 2:00 AM | American Alternative (Ad)LAVA Therapeutics NV Reports Q4 2024 EPS of -0.30, Revenue of $2. ...March 28, 2025 | gurufocus.comHC Wainwright & Co. Downgrades LAVA Therapeutics N.V. (LVTX)February 28, 2025 | msn.comLava Therapeutics downgraded to Neutral from Buy at H.C. WainwrightFebruary 27, 2025 | markets.businessinsider.comLAVA Therapeutics N.V.: LAVA Announces Evaluation of Strategic OptionsFebruary 25, 2025 | finanznachrichten.deLAVA Announces Evaluation of Strategic OptionsFebruary 25, 2025 | finance.yahoo.comSee More Headlines LAVA Stock Analysis - Frequently Asked Questions What other stocks do shareholders of LAVA Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LAVA Therapeutics investors own include Inovio Pharmaceuticals (INO), Sprott Physical Silver Trust (PSLV), MAG Silver (MAG). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:LAVA CIK1065034 Webwww.magma-da.com Phone+1-408-5657500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NASDAQ:LAVA) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics NV Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.